This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 4 Q&As
Facts about Annexin A7.
Human | |
---|---|
Gene Name: | ANXA7 |
Uniprot: | P20073 |
Entrez: | 310 |
Belongs to: |
---|
annexin family |
Annexin A7; ANX7; ANXA7; SNX; Synexin
Mass (kDA):
52.739 kDA
Human | |
---|---|
Location: | 10q22.2 |
Sequence: | 10; NC_000010.11 (73375101..73414058, complement) |
Isoform 1 is expressed in brain, heart and skeletal muscle. Isoform 2 is more abundant in liver, lung, kidney, spleen, fibroblasts and placenta.
The ANXA7 Marker Test consists of two key components: High-affinity primary antibody and detection methods. The detection methods include capturing the target and recording the results. Boster Bio has high-affinity prima antibodies that can be used for the detection of ANXA7 by multiple assays. Boster Bio has developed the highest-quality antibodies using proprietary trade secrets.
The distribution of ANXA7 protein in different cancers is related to its tumor suppressor role. It is involved in neurotransmitter and hormone secretion as well as carcinogenesis. These properties make it a useful therapeutic target for cancer diagnosis and tumor therapy. We review the detection methods for ANXA7 markers. You can also learn more about the cellular immunefluorescence methods that were used to analyze the ANXA7 markers.
Currently, a variety of detection methods for the ANxA7 gene are being developed. The Annexin VII DNA gene is composed 14 exons. It spans 34 kb. An mRNA containing the cassette endon is usually produced. This results in two transcripts with different biological functions. The exon has a tissue-specific function and is found in the heart and skeletal muscle. Poly (A) signals can also be used to identify transcripts of mRNA in the 3' noncoding region.
ANXA7 was associated with hormones that cause cancer. Prostate cancer cells have lost their ability to produce the protein, which suggests that ANXA7 works as a tumor suppressor. Several patterns that are diagnostically significant in ANXA7 were associated with tumor behavior, and the expected outcome. In addition, cancer progression in the breast and prostate shared a reduction in ANXA7 protein expression. Apoptosis was caused by decreased expression of the protein within breast cancer cells and prostate.
The tissue microarray method, which has revealed a large number molecular markers in cancer patients, is one of the detection methods for the ANxA7 indicator. These results indicate that ANXA7 is a useful clinical marker for cancer. It has been shown to be effective in prostate cancer. This protein is a tumor suppression agent with several clinical uses. It also regulates cell movement and invasion.
Using gene-specific primers that target PI3K–Akt and TUNEL–based APO–BRDU kits, detection methods for the ANxA7 marker were validated. These two kits use different methods to detect ANXA7. This article summarizes the most popular detection methods for ANxA7. However, you can also perform other tests to determine if ANxA7 is a reliable candidate for your cancer diagnosis.
Anxa7 is a novel gene that plays a role in cell survival. This discovery could lead to new therapeutic strategies for aggressive breast cancer cells. This discovery is not conclusive, however, further research is required to determine its role. We review the key findings of studies using ANXA7 in mice and humans. We also discuss the possible role of this gene for predicting the outcome to cancer.
ANXA7 comes from the annexin clan. It is composed of 14 exons. It spans 34 kb of genomic DNA. Only five exons of this exon are shared between humans and mice. However, there are significant differences in the exons that code C-terminal repeats. It could have diverged slightly from the evolutionary pathway of ANXA1 & ANXA2 gene genes. Its mouse homolog is composed of 14 exons, and has 30 kb in genomic DNA.
The binding of ALG-2 is achieved by the protein ANXA7. Additional experiments were conducted using non-vesicular membrane patch with open edges. AnxA7-GFP induces a pearl-like membrane conformation. It was shown that recombinant ANXA7 triggers ALG-2 membrane binding. These patches were able to absorb ALG-2 protein from ANXA7 -GFP.
The recruitment of ALG-2 or ALIX can be facilitated by the protein ANXA7. It also triggers the formation of ESCRT III on the site of injury. It is then shed during repairs. This gene plays an important part in the formation of the ectosome. This gene has been identified by the first genetic test. This gene could also be used in the future for diagnosing other diseases, such cancer.
The ANNXA7 Gene is a novel marker to Parkinson's Disease. It has been identified as a potential therapeutic target in neurological disorders. It is being developed for cancer therapy as part of a clinical trial for a new drug. A pCMV AC mRFP expression Vector has been developed to be used with ANXA7-tagged mice. SiRNA-tagged Annexin A7 knockdown reduces early brain injury following SAH.
Using ANxA7 as a marker, it is necessary to take several steps in order to create high-affinity primaries antibodies. To reduce cross-reactivity, HSA and IgG must be removed from antibodies. The light- and heavy chains must then be separated by either selective elution oder denaturing. This marker was used to develop a high-affinity primary antibody.
In a separate study a high-affinity IgM antibodies was generated against annexin XI. This calcyclin-associated protein has a molar mass of 56,000 Da. Antibodies against this antigen were found in serum samples from patients with systemic autoimmune diseases. To validate this result, the researchers performed immunoblotting assays using a HeLa cell extract.
Indirect IF confirmed the affinity maturation results. The PRIgM had a high affinity for the AM/PM, respectively. These antibodies were diluted with equal concentrations using HEp-2 to target cells and visualized by ANA-IgM–FITC. These experiments were conducted using Axioskop 2 (DMi8) software.
The label could be part of the binding agent. In some cases, multiple tethered bound agents may be used. The binding agents may be incorporated into precipitations, wells, or a mixture of both. Another application of the invention is affinity-selective IgDmicrovesicles. They are useful in identifying the ANXA7 antibody and a wide variety of other biomolecules.
In autoimmune diseases, autoantibodies against ANXA7 are essential. These antibodies are derived from B cells lacking the sIgD marker. Although the mechanism behind high-affinity antibodies against DsDNA is not clear, IgD-deficient mice develop high affinity antibodies against it at a young age. The research has implications on personalized medicine development. And we will continue to study this exciting new technique for ensuring that it becomes a routine.
The ANXA7 antibody marker is a highly selective and sensitive immunoglobulin (IgM), antigen. This marker can be used for the identification of a specific antigen. This is one way you can ensure high-affinity primaries antibodies. High-affinity IgM antibodies are highly multireactive. Their reactivity, however, is still limited. This study demonstrates that IgM antibodies are critical for an efficient secondary immune response.
To determine the clinical value of ANXA7, the protein abundance was measured by tissue microarray. The protein abundance for Annexin A7 was correlated with Ki67 and Bcl-2, p53 and syndecan-1. To indicate statistical significance, p values were below 0.05. The following table summarises the detection methods for ANXA7.
ANXA7 (transcription factor) regulates PG synthesis, and endometrial receptivity. The gene is present in the endometrium. Genetic knockout of ANXA7 in mice results in an increase litter size and a longer window for implantation. Low levels in RPL women can compromise fertility.
AnxA07 markers can be detected using a variety of detection methods. A single test may detect a high level of AnxA7 in a sample. Multiple tests, however, can determine the presence of more or less tumors. Numerous studies have also demonstrated a bimodal function of ANXA7 for prostate cancer. Interestingly, the bimodal nature of the protein is also thought to contribute to the bimodal nature of its roles.
Expression was associated to poor prognosis in tumors containing high levels of ANXA7. A poor prognosis was also associated with tumors with low levels ANXA7 protein expression. On the other hand, tumors with high levels of ANXA7 had a good prognosis. The most aggressive tumors also express high levels ANXA7.
PMID: 2542947 by Burns A.L., et al. Calcium channel activity of purified human synexin and structure of the human synexin gene.
PMID: 7515686 by Shirvan A., et al. Divergent structure of the human synexin (annexin VII) gene and assignment to chromosome 10.
*More publications can be found for each product on its corresponding product page